Skip to content
SEC EDGARcompany profilefree

JOHNSON & JOHNSON due diligence

Who JOHNSON & JOHNSON (JNJ) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1000 filings in EDGAR's recent index487 of them Form 4 filingsview the filings on SEC EDGARsource: SEC EDGAR, XBRL data

At a glance

JOHNSON & JOHNSON (JNJ) is a large accelerated filer incorporated in New Jersey, classified under SIC 2834 (Pharmaceutical Preparations), and lists on NYSE. Its fiscal year ends January 3. It has also filed as JOHNSON & JOHNSON ET AL.

For the fiscal year ended December 28, 2025, its 10-K reported revenue of $94.2B, up 6.0% from the year before, net income of $26.8B, and total assets of $199B.

In the twelve months to November 21, 2026 it made 115 filings on EDGAR, including 1 annual report, 3 quarterly reports, 8 current reports on Form 8-K, and 63 Form 4 insider filings. Its 8-Ks were filed most often for results of operations (4), Regulation FD disclosures (2), and officer or director changes (1).

CIK
0000200406
Filer status
Large accelerated filer
Industry (SIC)
Pharmaceutical Preparations (2834)
Incorporated
New Jersey
Listed on
NYSE
Tickers
JNJ
Fiscal year end
01-03

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-28$94.2B +6.0%$26.8B +90.6%$199B
2024-12-29$88.8B +4.3%$14.1B -60.0%$180B
2023-12-31$85.2B$35.2B$168B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag RevenueFromContractWithCustomerExcludingAssessedTax); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-112025-12-280000200406-26-000016
Quarterly report (10-Q)2026-10-212026-09-270000200406-26-000197
Current report (8-K)2026-10-132026-10-130000200406-26-000189

Filing activity

115 filings since 2025-11-21. By form:

Form 4
63
Form 144
18
8-K
8
13F-HR
4
SCHEDULE 13G/A
4
10-Q
3
11-K
2
13F-HR/A
2

8-K items in the last 12 months: results of operations (Item 2.02, 4) · Regulation FD disclosures (Item 7.01, 2) · officer or director changes (Item 5.02, 1) · shareholder vote results (Item 5.07, 1) · other events (Item 8.01, 1).

FiledFormDocumentPeriod
2026-11-134FORM 42026-11-12
2026-11-12144Form 144 notice of proposed sale
2026-10-2613F-HRForm 13F-HR filing2026-09-30
2026-10-2110-QQuarterly report2026-09-27
2026-10-138-KCurrent report on Form 8-K2026-10-13
2026-09-104FORM 42026-09-08
2026-09-104FORM 42026-09-08
2026-09-104FORM 42026-09-08
2026-09-044FORM 42026-09-02
2026-09-02144Form 144 notice of proposed sale
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on JOHNSON & JOHNSON

The free view above is the filing record: identity, annual results and the last year of filings. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"JNJ"} over x402 or MPP, $0.85

Sample output and API docsall reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.